Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting

References

• American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders5th edArlington VAAmerican Psychiatric Association2013
   Google Scholar
• DruaisSDoutriauxACognetMCost effectiveness of paliperidone long-acting injectable versus other antipsychotics for the maintenance treatment of schizophrenia in FrancePharmacoeconomics201634436339126883132
   PubMed Web of Science ®Google Scholar
• LeuchtSTardyMKomossaKHeresSKisslingWDavisJMMaintenance treatment with antipsychotic drugs for schizophreniaCochrane Database Syst Rev20125CD008016
   PubMed Web of Science ®Google Scholar
• ZipurskyRBMenezesNMStreinerDLRisk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic reviewSchizophr Res20141522–340841423972821
   PubMed Web of Science ®Google Scholar
• De HertMSermonJGeertsPVansteelandtKPeuskensJDetrauxJThe use of continuous treatment versus placebo or intermittent treatment strategies in stabilized patients with schizophrenia: a systematic review and meta-analysis of randomized controlled trials with first- and second-generation antipsychoticsCNS Drugs201529863765826293744
   PubMed Web of Science ®Google Scholar
• KishimotoTRobenzadehALeuchtCLong-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trialsSchizophr Bull201440119221323256986
   PubMed Web of Science ®Google Scholar
• SampsonSJoshiKMansourMAdamsCEIntermittent drug techniques for schizophreniaSchizophr Bull201339596096123861538
   PubMed Web of Science ®Google Scholar
• LiebermanJAStroupTSMcevoyJPClinical Antipsychotic Trials of Intervention Effectiveness (CATIE) InvestigatorsEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med2005353121209122316172203
   PubMed Web of Science ®Google Scholar
• GoffDCHillMFreudenreichOStrategies for improving treatment adherence in schizophrenia and schizoaffective disorderJ Clin Psychiatry201071Suppl 2202621190649
   PubMed Web of Science ®Google Scholar
• KarsonCDuffyRAEramoANylanderAGOffordSJLong-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic reviewNeuropsychiatr Dis Treat201612576726792993
   PubMed Web of Science ®Google Scholar
• StahlSMLong-acting injectable antipsychotics: shall the last be first?CNS Spectr20141913524512639
   PubMed Web of Science ®Google Scholar
• StevensGLDawsonGZummoJClinical benefits and impact of early use of long-acting injectable antipsychotics for schizophreniaEarly Interv Psychiatry201610536537726403538
   PubMed Web of Science ®Google Scholar
• KirsonNYWeidenPJYermakovSEfficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designsJ Clin Psychiatry201374656857523842008
   PubMed Web of Science ®Google Scholar
• van HarenNEHulshoff PolHESchnackHGFocal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up studyNeuropsychopharmacology200732102057206617327887
   PubMed Web of Science ®Google Scholar
• CastilloEGStroupTSEffectiveness of long-acting injectable antipsychotics: a clinical perspectiveEvid Based Ment Health2015182363925854825
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Mental Health (UK)Psychosis and Schizophrenia in Adults: Treatment and Management Updated Edition 2014, NICE Clinical Guidelines, No. 178LondonNational Institute for Health and Care Excellence (UK)2014
   Google Scholar
• LehmanAFLiebermanJADixonLBAmerican Psychiatric Association; Steering Committee on Practice GuidelinesPractice guideline for the treatment of patients with schizophrenia, second editionAm J Psychiatry20041612 Suppl156
   PubMed Web of Science ®Google Scholar
• MooreTASchizophrenia treatment guidelines in the United StatesClin Schizophr Relat Psychoses201151404921459738
   PubMedGoogle Scholar
• GalletlyCCastleDDarkFRoyal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disordersAust N Z J Psychiatry201650541047227106681
   PubMed Web of Science ®Google Scholar
• Fusar-PoliPKemptonMJRosenheckRAEfficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trialsInt Clin Psychopharmacol2013282576623165366
   PubMed Web of Science ®Google Scholar
• MisawaFKishimotoTHagiKKaneJMCorrellCUSafety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychoticsSchizophr Res20161762–322023027499361
   PubMed Web of Science ®Google Scholar
• LeuchtCHeresSKaneJMKisslingWDavisJMLeuchtSOral versus depot antipsychotic drugs for schizophrenia – a critical systematic review and meta-analysis of randomised long-term trialsSchizophr Res20111271–3839221257294
   PubMed Web of Science ®Google Scholar
• KaneJMKishimotoTCorrellCUAssessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatryJ Clin Epidemiol2013668 SupplS37S4123849151
   PubMed Web of Science ®Google Scholar
• PeuskensJOlivaresJMPecenakJTreatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countriesCurr Med Res Opin201026350150920014981
   PubMed Web of Science ®Google Scholar
• TiihonenJHaukkaJTaylorMHaddadPMPatelMXKorhonenPA nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophreniaAm J Psychiatry2011168660360921362741
   PubMed Web of Science ®Google Scholar
• KishimotoTNittaMBorensteinMKaneJMCorrellCULong-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studiesJ Clin Psychiatry2013741095796524229745
   PubMed Web of Science ®Google Scholar
• MarcusSCZummoJPettitARStoddardJDoshiJAAntipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital DischargeJ Manag Care Spec Pharm201521975476926308223
   PubMed Web of Science ®Google Scholar
• CorrellCUCitromeLHaddadPMThe Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the EvidenceJ Clin Psychiatry201677Suppl 312427732772
   PubMed Web of Science ®Google Scholar
• FagioliniARoccaPde GiorgiSSpinaEAmodeoGAmoreMClinical trial methodology to assess the efficacy/effectiveness of long-acting antipsychotics: Randomized controlled trials vs naturalistic studiesPsychiatry Res201724725726427936437
   PubMed Web of Science ®Google Scholar
• TiihonenJMittendorfer-RutzEMajakMReal-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With SchizophreniaJAMA Psychiatry201774768669328593216
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyCommittee for Medicinal Products for Human Use (CHMP).)Haldol Decanoate and Associated Names: Assessment ReportEMA/217985/20172017
   Google Scholar
• KaneJMDavisJMSchoolerNA multidose study of haloperidol decanoate in the maintenance treatment of schizophreniaAm J Psychiatry2002159455456011925292
   PubMed Web of Science ®Google Scholar
• MaroisMJRoyMAHaloperidol decanoate doses of 200, 100, or 50 mg/month reduced symptomatic exacerbations more than a 25 mg/month dose in schizophreniaEvid Based Ment Health20025411312440454
   PubMedGoogle Scholar
• De CuyperHBollenJvan PraagHMVerstraetenDPharmacokinetics and therapeutic efficacy of haloperidol decanoate after loading dose administrationBr J Psychiatry198614855605662877701
   PubMed Web of Science ®Google Scholar
• QuraishiSDavidADepot haloperidol decanoate for schizophreniaCochrane Database Syst Rev20002CD001361
   Google Scholar
• Paliperidone Palmitate: EPARProduct InformationLondon:European Medicines AgencyEMEA/H/C/21052011
   Google Scholar
• MorrisMTTarpadaSPLong-acting injectable paliperidone palmitate: a review of efficacy and safetyPsychopharmacol Bull2017472425228626271
   PubMedGoogle Scholar
• SchreinerABergmansPCherubinPA prospective flexible-dose study of paliperidone palmitate in nonacute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral antipsychotic agentsClin Ther201436101372138825444566
   PubMed Web of Science ®Google Scholar
• HargarterLCherubinPBergmansPIntramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychoticsProg Neuropsychopharmacol Biol Psychiatry2015581725448776
   PubMed Web of Science ®Google Scholar
• SchreinerABergmansPCherubinPPaliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychoticsJ Psychopharmacol201529891092225999398
   PubMed Web of Science ®Google Scholar
• WilliamsWMckinneyCMartinezLBensonCRecovery outcomes of schizophrenia patients treated with paliperidone palmitate in a community setting: patient and provider perspectives on recoveryJ Med Econ201619546947626671481
   PubMed Web of Science ®Google Scholar
• AttardAOlofinjanaOCorneliusVCurtisVTaylorDPaliperidone palmitate long-acting injection – prospective year-long follow-up of use in clinical practiceActa Psychiatr Scand20141301465124117209
   PubMed Web of Science ®Google Scholar
• RossoGPessinaEMartiniAdi SalvoGMainaGPaliperidone Palmitate and Metabolic Syndrome in Patients With Schizophrenia: A 12-Month Observational Prospective Cohort StudyJ Clin Psychopharmacol201636320621227043122
   PubMed Web of Science ®Google Scholar
• Di LorenzoRCameliMBolondiMPaliperidone palmitate treatment in outpatient care setting: a naturalistic studyPsychopharmacol Bull2016461365327738372
   PubMedGoogle Scholar
• KaneJMSanchezRPerryPPAripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled studyJ Clin Psychiatry201273561762422697189
   PubMed Web of Science ®Google Scholar
• IshigookaJNakamuraJFujiiYEfficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazoleSchizophr Res20151612–342142825556976
   PubMed Web of Science ®Google Scholar
• FleischhackerWWSanchezRJohnsonBLong-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophreniaInt Clin Psychopharmacol2013284117623138680
   PubMed Web of Science ®Google Scholar
• ShirleyMPerryCMAripiprazole (ABILIFY MAINTENA): a review of its use as maintenance treatment for adult patients with schizophreniaDrugs201474101097111024969315
   PubMed Web of Science ®Google Scholar
• KahnRSGiannopoulouAThe safety, efficacy and tolerability of Abilify Maintena for the treatment of schizophreniaExpert Rev Neurother201515996998126289486
   PubMed Web of Science ®Google Scholar
• FagioliniAAlfonsiEAmodeoGSwitching long acting anti-psychotic medications to aripiprazole long acting once-a-month: expert consensus by a panel of Italian and Spanish psychiatristsExpert Opin Drug Saf201615444945526886162
   PubMed Web of Science ®Google Scholar
• BiagiECapuzziEColmegnaFLong-acting injectable antipsychotics in schizophrenia: literature review and practical perspective, with a focus on aripiprazole once-monthlyAdv Ther20173451036104828382557
   PubMed Web of Science ®Google Scholar
• PandinaGJLindenmayerJPLullJA randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophreniaJ Clin Psychopharmacol201030323524420473057
   PubMed Web of Science ®Google Scholar
• LiHRuiQNingXXuHGuNA comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophreniaProg Neuropsychopharmacol Biol Psychiatry20113541002100821315787
   PubMed Web of Science ®Google Scholar
• NussbaumAMStroupTSPaliperidone palmitate for schizophreniaCochrane Database Syst Rev20126CD008296
   PubMed Web of Science ®Google Scholar
• CovellNHMcevoyJPSchoolerNREffectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trialJ Clin Psychiatry201273566967522480442
   PubMed Web of Science ®Google Scholar
• LammersLZehmBWilliamsRRisperidone long-acting injection in Schizophrenia Spectrum Illnesses compared to first generation depot antipsychotics in an outpatient setting in CanadaBMC Psychiatry201313115523718192
   PubMed Web of Science ®Google Scholar
• YuHYHsiaoCYChenKCA comparison of the effectiveness of risperidone, haloperidol and flupentixol long-acting injections in patients with schizophrenia-A nationwide studySchizophr Res20151691–340040526395153
   PubMed Web of Science ®Google Scholar
• McevoyJPByerlyMHamerRMEffectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trialJAMA2014311191978198724846035
   PubMed Web of Science ®Google Scholar
• CordinerMShajahanPMcavoySBashirMTaylorMEffectiveness of long-acting antipsychotics in clinical practice: 1. A retrospective, 18-month follow up and comparison between paliperidone palmitate, risperidone long-acting injection and zuclopenthixol decanoateTher Adv Psychopharmacol201661223226913175
   PubMed Web of Science ®Google Scholar
• NaberDHansenKForrayCQualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophreniaSchizophr Res20151681–249850426232241
   PubMed Web of Science ®Google Scholar
• PaeCUWangSMHanCComparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia: systematic review and indirect treatment comparisonInt Clin Psychopharmacol201732523524828430670
   PubMed Web of Science ®Google Scholar
• SapinCHartryAKamatSBeillatMBakerREramoAPharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysisDrugs in Context2016518
   Google Scholar
• EinarsonTRPudasHGoswamiPvan ImpeKBerezaBGPharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in FinlandJ Med Econ201619212113026413789
   PubMed Web of Science ®Google Scholar
• DecuypereFSermonJGeertsPTreatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database studyPLoS One2017126e017904928614404
   PubMed Web of Science ®Google Scholar
• JoshiKPanXWangRYangEBensonCHealthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitateCurr Med Res Opin201632111873188127479694
   PubMed Web of Science ®Google Scholar
• QuinteroJOyagüezIGonzálezBCuervo-ArangoIGarcíaICasadoMACost-minimisation analysis of paliperidone palmitate long-acting treatment versus risperidone long-acting treatment for schizophrenia in SpainClin Drug Investig2016366479490
   Web of Science ®Google Scholar
• MiyamotoSWolfgang FleischhackerWThe Use of Long-Acting Injectable Antipsychotics in SchizophreniaCurr Treat Options Psychiatry20174211712628580230
   PubMedGoogle Scholar
• Ministry of Labor, Health and Social PoliciesICD-9-CM: International Classification of Diseases, 9th revision, Clinical Modification, 2007. Italian editionRomaIstituto poligrafico e Zecca dello Stato2008
   Google Scholar
• BusnerJTargumSDThe clinical global impressions scale: applying a research tool in clinical practicePsychiatry2007472837
   PubMedGoogle Scholar
• AasIHGuidelines for rating Global Assessment of Functioning (GAF)Ann Gen Psychiatry2011101221251305
   PubMed Web of Science ®Google Scholar
• VerdouxHPambrunETournierMBezinJParienteAAntipsychotic long-acting injections: a community-based study from 2007 to 2014 of prescribing trends and characteristics associated with initiationSchizophr Res20161781–3586327624680
   PubMed Web of Science ®Google Scholar
• KaneJMSanchezRZhaoJHospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophreniaJ Med Econ201316791792523663091
   PubMedGoogle Scholar
• KaneJMZhaoCJohnsonBRHospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysisJ Med Econ201518214515425347448
   PubMed Web of Science ®Google Scholar
• TaylorDMSparshattAO’HaganMDzahiniOEffect of paliperidone palmitate on hospitalisation in a naturalistic cohort – a four-year mirror image studyEur Psychiatry201637434827447102
   PubMed Web of Science ®Google Scholar
• Di LorenzoRCameliMPiemonteCClinical improvement, relapse and treatment adherence with paliperidone palmitate 1-month formulation: 1-year treatment in a naturalistic outpatient settingNord J Psychiatry201872321422029278968
   PubMed Web of Science ®Google Scholar
• PatelMXHaddadPMChaudhryIBMcloughlinSDavidASPsychiatrists’ use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 yearsJ Psychopharmacol201024101473148219477883
   PubMed Web of Science ®Google Scholar
• IyerSBanksNRoyM-AA qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: Part I-patient perspectivesCan J Psychiatry2013585 Suppl 11422
   Web of Science ®Google Scholar
• AggarwalNKRosenheckRAWoodsSWSernyakMJRace and long-acting antipsychotic prescription at a community mental health center: a retrospective chart reviewJ Clin Psychiatry201273451351722579151
   PubMed Web of Science ®Google Scholar
• TaylorDMSparshattAAminFAripiprazole long-acting injection – a mirror image study of its effects on hospitalisation at one yearJ Psychopharmacol201731121564156929039241
   PubMed Web of Science ®Google Scholar
• VincentPDDemersMFDoyon-KempVDuchesneauJHalmeAMassonVOne year mirror-image study using paliperidone palmitate for relapse prevention of schizophrenia in four university hospitals in CanadaSchizophr Res20171859610028119036
   PubMed Web of Science ®Google Scholar
• TaylorDMPatonCKapurSThe Maudsley Prescribing Guidelines in Psychiatry12th edChichesterWiley Blackwell2015
   Google Scholar
• LachaineJLapierreMEAbdallaNRouleauAStipEImpact of switching to long-acting injectable antipsychotics on health services use in the treatment of schizophreniaCan J Psychiatry2015603 Suppl 2S40S4725886679
   PubMedGoogle Scholar
• NielsenJJensenSOFriisRBValentinJBCorrellCUComparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort studySchizophr Bull201541362763625180312
   PubMed Web of Science ®Google Scholar
• WuCSChengICFengJChenCLComparison of treatment effectiveness and medical costs for different long-acting injectable antipsychotics in patients with schizophrenia in Taiwan: a nationwide population-based cohort studySchizophr Res20161731–2374426987938
   PubMed Web of Science ®Google Scholar
• MajerIMGaughranFSapinCBeillatMTreurMEfficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trialsJ Mark Access Health Policy2015327208
   PubMedGoogle Scholar
• WhaleRPereiraMCuthbertSFialhoREffectiveness and predictors of continuation of paliperidone palmitate long-acting injection treatment: a 12-month naturalistic cohort studyJ Clin Psychopharmacol201535559159526267419
   PubMed Web of Science ®Google Scholar
• JonesPBBarnesTRDaviesLRandomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)Arch Gen Psychiatry200663101079108717015810
   PubMed Web of Science ®Google Scholar